Received May 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | CT2Z7 | — |
Engerix-B inadvertent 20mcg dose to 19 year old; Engerix-B inadvertent 20mcg dose to 19 year old; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult product administered to child in a 19-year-old female patient who received HBV (Engerix B adult) (batch number CT2Z7) for prophylaxis. On 08-APR-2025, the patient received Engerix B adult. On 08-APR-2025, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: Engerix-B inadvertent 20mcg dose to 19 year old) and overdose (Verbatim: Engerix-B inadvertent 20mcg dose to 19 year old). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 08-MAY-2025 Pharmacist calls today on 08th May 2025 to report 19 years and 2-month-old patient received the adult dose inadvertently on 08th April 2025 which led to adult product administered to child and overdose. The Vaccine Administration Facility is the same as Primary Reporter.